76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Harvard Bioscience Inc
Open
SectorHealthcare
0.5 -3.85
Overview
Share price change
24h
Min
0.47
Max
0.53
Income | -50M -50M |
|---|---|
Sales | -2.8M 22M |
EPS | 0.06 |
Profit margin | -231.193 |
Employees | 330 |
EBITDA | -43M -40M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +466.04% upside |
Next Earnings | 7 Aug 2025 |
|---|
Market Cap | 7.1M 23M |
|---|---|
Previous open | 4.35 |
Previous close | 0.5 |
News Sentiment
By Acuity
50%
50%
165 / 380 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Harvard Bioscience Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Harvard Bioscience Inc Forecast
Price Target
By TipRanks
466.04% upside
12 Months Forecast
Average 3 USD 466.04%
High 3 USD
Low 3 USD
Based on 2 Wall Street analysts offering 12 month price targets forHarvard Bioscience Inc - Dist in the last 3 months.
Sentiment
By Acuity
165 / 380 Healthcare
News Sentiment
Neutral
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
